HIV Drug Combo May Be Risky in Early Pregnancy

Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.

HIV Drug Combo May Be Risky in Early Pregnancy

Reuters Health (12.26.01) - Friday, December 28, 2001

HIV-infected women who take certain combinations of medications in their first trimester of pregnancy may increase the risk of having a child with birth defects, a small study suggests. In particular, women who took a drug to ward off Pneumocystis carinii pneumonia (PCP) in combination with antiretroviral drugs early in pregnancy were more likely to have a baby with birth defects. However, taking either type of drug alone in early pregnancy did not seem to be a problem.

In the study, Dr. Graham Taylor from Imperial College in London and colleagues evaluated the risk of birth defects in infants of 195 HIV-infected mothers. Overall, nine children (4.6 percent) were born with abnormalities, the authors report. None of the 34 infants exposed to either antiretroviral drugs alone or PCP-preventing drugs alone during the first trimester had birth defects. In contrast, three of 13 (23.1 percent) children exposed to both therapies had birth defects, the report indicates. "Although the numbers are small, they had a sevenfold increased risk of birth defects compared with infants not exposed to any drugs during the first trimester," the authors wrote.

"These findings, if confirmed, have important implications for preconceptual counseling and the therapeutic choices of women of childbearing age," the authors concluded. Taylor said that physicians should take care "to regularly review the needs of therapy before women become pregnant and to ensure that women with HIV who wish to become pregnant, especially those who need to take PCP prophylaxis, take folic acid supplements." Drugs used to combat PCP are known as folate antagonists, meaning they deplete folate in the body. Folic acid has been found to help prevent birth defects when taken by women before and during early pregnancy. The findings are reported in the December issue of the journal Sexually Transmitted Infections (2001; 77: 441-443).
011228
AD012250

Copyright © 2001 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.